Because of the known complement activation see in GBS patients, recent clinical trials have examined the role of eculizumab (a humanized monoclonal antibody against C5 that prevents cleavage into C5a and C5b components) in patients with GBS (Davidson et al., 2017; Misawa et al., 2018). Here, C5 is linked to Guillain-Barre syndrome.